

ASX ANNOUNCEMENT

CHANGE OF AUDITOR

SYDNEY: Friday, 24 November 2017, Cellmid Limited (ASX: CDY) advises that in accordance with ASX Rule 3.16.3 Grant Thornton Audit Pty Ltd (**Grant Thornton**) has been appointed as auditor of the Company.

The appointment of Grant Thornton was approved on 23 November 2017 at the Annual General Meeting of shareholders, in accordance with Section 327 of the Corporation Act.

The Board wishes to thank BDO East Coast Partnership, the previous auditor, who have provided their services to the Company between 2010 to 2017.

End

Contact: Maria Halasz, CEO

T +612 9221 6830

 @mariahalsz

Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences company with lead programs in multiple disease indications. The Company, through its wholly owned subsidiaries, Lynamid, Kinera and Advangen, develops and markets innovative novel therapies and diagnostic tests for fibrotic diseases, cancer, ischemic diseases of the heart and hair loss. Cellmid holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) and FGF5 globally. Intellectual property pertaining midkine is being exploited through wholly owned subsidiaries Lynamid and Kinera. Advangen, Cellmid's consumer health business, sells its FGF5 inhibitor hair growth products in Australia, Japan and the USA and currently expanding distribution in other territories. For further information, please see www.cellmid.com.au and www.evolisproducts.com.au.